Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Income from Continuing Operations (2018 - 2026)

10x Genomics' Income from Continuing Operations history spans 8 years, with the latest figure at 16252000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 66.85% to 16252000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 43544000.0, a 76.16% increase, with the full-year FY2025 number at 43544000.0, up 76.16% from a year prior.
  • Income from Continuing Operations hit 16252000.0 in Q4 2025 for 10x Genomics, up from 27472000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TXG hit a ceiling of 34538000.0 in Q2 2025 and a floor of 92986000.0 in Q3 2023.
  • Historically, Income from Continuing Operations has averaged 35274650.0 across 5 years, with a median of 36825000.0 in 2024.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 483.22% in 2022 and later skyrocketed 191.14% in 2025.
  • Tracing TXG's Income from Continuing Operations over 5 years: stood at 18449000.0 in 2021, then increased by 6.69% to 17215000.0 in 2022, then plummeted by 184.36% to 48952000.0 in 2023, then decreased by 0.16% to 49028000.0 in 2024, then soared by 66.85% to 16252000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TXG at 16252000.0 in Q4 2025, 27472000.0 in Q3 2025, and 34538000.0 in Q2 2025.